ABILIFY ASIMTUFII Drug Patent Profile

When do Abilify Asimtufii patents expire, and what generic alternatives are available?

Abilify Asimtufii is a drug marketed by Otsuka and is included in one NDA. There are four patents protecting this drug.

This drug has seventy-four patent family members in thirty-one countries.

The generic ingredient in ABILIFY ASIMTUFII is aripiprazole. There are forty-nine drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify Asimtufii

A generic version of ABILIFY ASIMTUFII was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY ASIMTUFII

International Patents:	74
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY ASIMTUFII

US Patents and Regulatory Information for ABILIFY ASIMTUFII

ABILIFY ASIMTUFII is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No	12,016,927		Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No	10,517,951		Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No	11,638,757		Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-001	Apr 27, 2023		RX	Yes	No	11,097,007		Y
Otsuka	ABILIFY ASIMTUFII	aripiprazole	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	217006-002	Apr 27, 2023		RX	Yes	Yes	10,517,951		Y

International Patents for ABILIFY ASIMTUFII

See the table below for patents covering ABILIFY ASIMTUFII around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003212852	ARIPIPRAZOLE HYDRATE, ARIPIPRAZOLE ANHYDRIDE CRYSTAL, PREPARATION THEREOF AND MEDICINAL PREPARATION CONTAINING THE SAME
Canada	2426921	SUBSTANCE PHARMACEUTIQUE D'ARIPIPRAZOLE FAIBLEMENT HYGROSCOPIQUE ET METHODES DE PREPARATION ASSOCIEES (LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF)
Japan	3760264
Japan	6470378
Japan	2019070028

Supplementary Protection Certificates for ABILIFY ASIMTUFII

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

ABILIFY ASIMTUFII Investment Scenario and Fundamentals Analysis

Last updated: April 23, 2026

What is ABILIFY ASIMTUFII and why does it matter commercially?

ABILIFY ASIMTUFII is a long-acting injectable (LAI) formulation of aripiprazole, branded for schizophrenia. It is a once-every-4-weeks depot product aimed at improving adherence versus oral aripiprazole and helping sustain market share amid competition from other LAIs and branded/oral generics.

Core commercial relevance is driven by:

• LAI category stickiness and switching costs (patients and prescribers anchor to injection schedules).
• Formulation-driven differentiation (4-week dosing for a subset of patients).
• Margin structure tied to branded status, contracting, and distribution channels.

What indications and regulatory basis define the product?

ABILIFY ASIMTUFII is positioned for:

• Schizophrenia (maintenance of efficacy; dosing schedule is monthly).

Key practical attributes that affect payer and provider adoption:

• Once-monthly injection reduces missed doses versus oral therapy.
• LAI administration creates structured clinic workflows and ongoing treatment continuity.

How does the product fit into aripiprazole’s franchise and competitive landscape?

ABILIFY ASIMTUFII competes in two layers:

1. Within aripiprazole LAIs
   • It expands the aripiprazole LAI lineup by offering a monthly option.
2. Across LAI antipsychotics
   • Competes with other LAIs used for schizophrenia maintenance, where payers evaluate cost per month and clinical switching outcomes.

Investment implications:

• If the product gains formulary access and clinic protocols, it can compound share over time through routine injection cycles.
• If payers push step therapy toward lower-cost alternatives or steer to competing LAIs, unit economics can compress faster than for oral branded assets.

What are the key demand drivers for ABILIFY ASIMTUFII?

Demand is anchored to measurable prescribing behaviors and economics:

1. Adherence and relapse prevention
   • LAIs reduce nonadherence, which is linked to relapse and downstream utilization.
2. Conversion from oral aripiprazole
   • Conversion flows come from clinics managing adherence challenges and from psychiatrists who prefer depot regimens for maintenance.
3. Clinic capacity and injection cadence
   • Monthly dosing reduces scheduling burden relative to shorter-interval regimens, supporting sustained administration.

What are the main supply, pricing, and payer adoption constraints?

The biggest real-world adoption gates tend to be:

• Formulary placement (commercial and managed Medicaid lines).
• Prior authorization and documentation rules (often aligned to diagnosis confirmation, treatment history, and response criteria).
• Contracting with group purchasing organizations (GPOs) and channel partners.

For investment modeling, these constraints typically manifest as:

• Time-lagged uptake after initial approvals and label expansions.
• Rapid profitability inflection when net price stabilizes and conversion targets are met.
• Higher churn risk when payers introduce new preferred LAIs or tighten criteria.

What does the patent and exclusivity landscape imply for the investment horizon?

Investment decisions on LAI assets depend on:

• Regulatory exclusivity timelines
• Patent term remaining for composition of matter, method of use, and formulation
• Risk of biosimilar-style entry does not apply (small molecule), but generic competition does.

Aripiprazole is an older active ingredient; therefore, the investment hinge is the specific formulation, dosing, and delivery technology protected by relevant patent coverage and any exclusivity extensions rather than the underlying drug substance alone.

What is the likely lifecycle shape (adoption, margin, and erosion)?

For branded LAIs:

• Early period: adoption through payer access and clinic conversion ramps.
• Mid period: net sales grow with increasing patient base; gross margin stabilizes as channel discounts normalize.
• Late period: margin erosion accelerates as competing LAIs and generics enter the relevant segments.

For ABILIFY ASIMTUFII specifically, the key question for fundamentals is how much differentiation persists once pricing pressure arrives through payer contracting and LAI competition.

How should an investor frame fundamentals and valuation for ABILIFY ASIMTUFII?

Use a three-layer model: (1) unit and patient base growth, (2) net price and margin, (3) durability from payer and competitive position.

1) Unit growth and patient base (drivers and KPIs)

• New starts per month: conversions from oral aripiprazole and switches from other LAIs.
• Persistence: proportion of patients remaining on the injection schedule at 6, 12, and 24 months.
• Dose share: monthly injection share among eligible schizophrenia patients managed with LAIs.

2) Net price and margin (what moves the earnings line)

• Contracted net price versus wholesale acquisition cost (WAC).
• Rebate intensity and channel mix (commercial vs. specialty channel structures).
• Administration economics: injection administration does not always flow through the drug P&L; model provider mix separately.

3) Durability (how long the asset holds price and share)

• Formulary retention and the number of lines of business where the product is preferred.
• Competitive responses by other LAI manufacturers.
• Pipeline of near-term switching options (new LAIs or improved scheduling options).

What are the key investment scenarios?

Scenario A: Formulary expansion and strong persistence

Assumptions

• Broad managed care uptake.
• Stable persistence at high rates.
• Net price holds with limited competitive substitution.

Fundamentals

• Faster ramp in prescriptions and sustained share.
• Higher gross profit per patient due to stable net pricing.

Investor read-through

• Valuation supports a longer period of premium franchise behavior within LAIs.

Scenario B: Payer steering and higher rebate intensity

Assumptions

• PA requirements and step edits increase.
• Net price declines as payers reprice against competitors.
• Persistence remains acceptable, but starts slow.

Fundamentals

• Volume grows but margin compresses.
• Earnings growth lags prescription growth.

Investor read-through

• Valuation should discount sooner for margin compression.

Scenario C: Competitive LAI displacement

Assumptions

• Competitors deliver better payer economics or clinician preference.
• Switching increases and persistence deteriorates relative to expectations.

Fundamentals

• Share erosion hits before price erosion because prescribers follow contracting and ease-of-use.
• Cash flows become more volatile.

Investor read-through

• Valuation should apply steeper decline curves and higher probability-weighting to downside.

What are the concrete near-term diligence items for investors?

Even when the label is stable, LAI performance is often decided by operational and contracting realities:

• Formulary coverage map by payer segment (commercial vs. Medicaid vs. Medicare Advantage).
• Utilization management strictness (PA frequency, documented failure requirements).
• Channel inventory health and distribution stability to avoid supply-driven revenue volatility.
• Persistence cohort analysis: discontinuation timing and reasons (switching vs. discontinuation vs. payer-driven changes).

What are the principal risks specific to ABILIFY ASIMTUFII?

Risk categories that typically drive downside for branded LAIs:

• Pricing and rebate reset risk under payer renegotiation.
• Switching risk if competing LAIs offer a better economics or dosing cadence.
• Operational risk from injection logistics (clinic readiness, scheduling, and patient acceptance).
• Regulatory and label change risk impacting eligibility and reimbursement.

Key Takeaways

• ABILIFY ASIMTUFII is an aripiprazole LAI with a monthly dosing cadence, built to capture adherence-focused schizophrenia maintenance demand.
• The investment case hinges on payer access, net price durability, and patient persistence, not on the aripiprazole molecule alone.
• Fundamentals should be modeled with unit growth (starts and persistence) plus net pricing and rebate pressure, then stress-tested against LAI competitive substitution.
• The patent and exclusivity posture for a formulation-specific LAI determines the earnings duration premium, while generic competition risk is likely managed through formulation and delivery protection rather than substance-level exclusivity.
• Near-term diligence should target formulary coverage, PA friction, and persistence cohorts, because those metrics explain most of the variance in LAI earnings outcomes.

FAQs

1. Is ABILIFY ASIMTUFII an oral or injectable product?
   It is a long-acting injectable (LAI).

2. What dosing cadence does ABILIFY ASIMTUFII use?
   It is designed as a once-every-4-weeks (monthly) injection regimen.

3. What is the primary commercial indication?
   Schizophrenia maintenance.

4. What metrics matter most for LAI investors beyond prescriptions?
   Persistence (staying on schedule) and net price after rebates and contracts.

5. Where does competitive pressure typically come from in LAIs?
   From competing LAI antipsychotics that can win formulary placement through pricing, contracting, and clinician adoption.

---

References

[1] U.S. Food and Drug Administration. Label information for ABILIFY ASIMTUFII (aripiprazole). (Latest label accessed via FDA labeling database). APA citation format as provided by FDA labeling entry.